Sociedad Americana de Hirudoterapia

Comparison of VTE prophylaxis agents on hemoglobin levels after total knee arthroplasty: a hospital information system-based observational study

Research article published in Journal of orthopaedic surgery and research (2025)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Observational studySeguridad y control de infeccionesYuan et al. · Journal of orthopaedic surgery and research, 2025

Abstract

BACKGROUND: While venous thromboembolism (VTE) prophylaxis is crucial following major orthopaedic surgeries including total knee arthroplasty (TKA), the impact of different prophylactic agents on postoperative hemoglobin (Hb) levels remains inadequately studied. The aim of this study was to compare the effects of aspirin, rivaroxaban, and low-molecular-weight heparin (LMWH) on early postoperative Hb changes following TKA. METHODS: In this single-center retrospective cohort study, 655 primary TKAs were finally included using data from the hospital information system. Patients received either aspirin, rivaroxaban, or LMWH for VTE prophylaxis. The primary outcome was the magnitude of Hb reduction, calculated as the difference between the Hb level on the first postoperative day and the minimum postoperative Hb level before discharge. The secondary outcome was the trajectory of postoperative Hb changes within the first week. RESULTS: Postoperative Hb levels clearly declined within the first week, with a mean of 13.9 g/L (SD, 8.5) from postoperative day 1 in the entire cohort. In the fully adjusted linear regression model, both rivaroxaban (β = 1.5, [95%CI, 0.0 to 3.0]) and low-molecular-weight heparin (LMWH) (β = 3.3, [95%CI, 1.5 to 5.2]) were associated with a greater reduction in Hb compared to aspirin. Regarding the trajectory of postoperative Hb changes, the generalized additive mixed model revealed no statistically significant difference between rivaroxaban and aspirin (β = -0.2, [95%CI, -0.6 to 0.2]). LMWH was associated with a greater daily reduction in Hb levels relative to aspirin, averaging 0.8 g/L per day (β = -0.8, [95%CI, -1.3 to -0.3]). Despite these observed differences, the effect sizes were small, suggesting a lack of clinical significance. CONCLUSIONS: Hemoglobin levels declined significantly following TKA within the first week after surgery. However, no clinically meaningful distinction is discernible between the three most frequently used pharmacological agents, aspirin, rivaroxaban and LMWH. LEVEL OF EVIDENCE: III, A retrospective cohort study.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleComparative StudyObservational Study
Indexed MeSH termsHumansArthroplasty, Replacement, KneeHemoglobinsMaleVenous ThromboembolismRetrospective StudiesFemaleAgedRivaroxabanAspirinHeparin, Low-Molecular-WeightMiddle Aged

Resumen

Peer-reviewed safety and infection-control research relevant to leech therapy and microsurgical wound management. Indexed in PubMed and verified against the NCBI record.

Por qué esto importa para la hirudoterapia

Esta cohorte retrospectiva de un solo centro de 655 artroplastias totales de rodilla primarias comparó la aspirina, el rivaroxaban y la heparin de bajo peso molecular (LMWH) para la profilaxis de VTE, midiendo el descenso temprano de la hemoglobina posoperatoria; aunque el rivaroxaban y la LMWH se asociaron estadísticamente con una reducción de Hb ligeramente mayor que la aspirina, los autores consideraron que los tamaños del efecto fueron pequeños y concluyeron que no hubo una diferencia clínicamente significativa entre los tres agentes. Para la hirudoterapia, el estudio proporciona un contexto útil sobre el equilibrio entre el sangrado y la pérdida de sangre de los anticoagulantes sistémicos en los mismos entornos quirúrgicos y de congestión microvascular donde el uso de sanguijuelas medicinales se emplea a veces como un complemento local en lugar de un anticoagulante sistémico. Al ser una cohorte retrospectiva de un solo centro calificada como evidencia de Nivel III por los autores, muestra asociación en lugar de causalidad, examina únicamente la profilaxis farmacológica y no dice nada directamente sobre la terapia con sanguijuelas.

Citación

Comparison of VTE prophylaxis agents on hemoglobin levels after total knee arthroplasty: a hospital information system-based observational study.

Yuan et al. · Journal of orthopaedic surgery and research, 2025

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Añadido a la biblioteca ASH: May 29, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.